1. Home
  2. HALO vs NIO Comparison

HALO vs NIO Comparison

Compare HALO & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • NIO
  • Stock Information
  • Founded
  • HALO 1998
  • NIO 2014
  • Country
  • HALO United States
  • NIO China
  • Employees
  • HALO N/A
  • NIO N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • NIO Auto Manufacturing
  • Sector
  • HALO Health Care
  • NIO Consumer Discretionary
  • Exchange
  • HALO Nasdaq
  • NIO Nasdaq
  • Market Cap
  • HALO 7.4B
  • NIO 7.4B
  • IPO Year
  • HALO N/A
  • NIO 2018
  • Fundamental
  • Price
  • HALO $58.79
  • NIO $3.52
  • Analyst Decision
  • HALO Buy
  • NIO Hold
  • Analyst Count
  • HALO 9
  • NIO 6
  • Target Price
  • HALO $61.63
  • NIO $5.05
  • AVG Volume (30 Days)
  • HALO 1.8M
  • NIO 61.9M
  • Earning Date
  • HALO 05-06-2025
  • NIO 06-05-2025
  • Dividend Yield
  • HALO N/A
  • NIO N/A
  • EPS Growth
  • HALO 63.33
  • NIO N/A
  • EPS
  • HALO 3.43
  • NIO N/A
  • Revenue
  • HALO $1,015,324,000.00
  • NIO $9,005,433,398.00
  • Revenue This Year
  • HALO $20.06
  • NIO $37.33
  • Revenue Next Year
  • HALO $24.04
  • NIO $25.76
  • P/E Ratio
  • HALO $17.14
  • NIO N/A
  • Revenue Growth
  • HALO 22.44
  • NIO 18.18
  • 52 Week Low
  • HALO $37.73
  • NIO $3.02
  • 52 Week High
  • HALO $66.00
  • NIO $7.71
  • Technical
  • Relative Strength Index (RSI)
  • HALO 44.06
  • NIO 39.90
  • Support Level
  • HALO $57.50
  • NIO $3.42
  • Resistance Level
  • HALO $62.14
  • NIO $3.71
  • Average True Range (ATR)
  • HALO 2.90
  • NIO 0.22
  • MACD
  • HALO -0.40
  • NIO 0.01
  • Stochastic Oscillator
  • HALO 36.41
  • NIO 51.02

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About NIO NIO Inc. American depositary shares each representing one ordinary share

Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.

Share on Social Networks: